These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7934365)

  • 41. [Ciprofibrate: erythrocyte partition coefficient and binding to serum protein].
    Czejka M
    Arch Pharm (Weinheim); 1991 May; 324(5):287-9. PubMed ID: 1888266
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M
    Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Conjugation reactions of ciprofibrate with human and laboratory animals].
    Oelschläger H; Müller D; Hellwich KH; Ueberall S; Seeling A; Machts H; Hofmann B; Glöckner R
    Arzneimittelforschung; 2003; 53(4):247-53. PubMed ID: 12785120
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metabolic effects of a new hypolipidemic agent, ciprofibrate.
    Arnold A; McAuliff MP; Beyler AL
    J Pharm Sci; 1979 Dec; 68(12):1557-8. PubMed ID: 529054
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The enantiomeric resolution of ciprofibrate and related compounds by HPLC using chiral stationary phases.
    Anderson NH; Johnston D; Vojvodic PR
    J Pharm Biomed Anal; 1992 Jul; 10(7):501-5. PubMed ID: 1420475
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The pharmacokinetics of hypolipemic agents. 10. The dehalogenation of the hypolipemic agent ciprofibrate].
    Oelschläger H; Hellwich KH; Rothley D
    Arch Pharm (Weinheim); 1994 Apr; 327(4):261-5. PubMed ID: 8204026
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate.
    Ferry N; Bernard N; Pozet N; Gardes E; Cuisinaud G; Labeeuw M; Zech PY; Sassard J
    Br J Clin Pharmacol; 1989 Dec; 28(6):675-81. PubMed ID: 2611089
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of ciprofibrate on gastric secretion in the rat.
    Eason CT; Pattison A; Howells DD; Bonner FW
    J Pharm Pharmacol; 1988 Jul; 40(7):512-3. PubMed ID: 2904995
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tolerability of fibric acids. Comparative data and biochemical bases.
    Sirtori CR; Calabresi L; Werba JP; Franceschini G
    Pharmacol Res; 1992; 26(3):243-60. PubMed ID: 1437989
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.
    Lupp A; Karge E; Deufel T; Oelschlägers H; Fleck C
    Arzneimittelforschung; 2008; 58(5):225-41. PubMed ID: 18589557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute muscular syndrome after bezafibrate.
    Bock KD
    Klin Wochenschr; 1981 Dec; 59(23):1321. PubMed ID: 7311399
    [No Abstract]   [Full Text] [Related]  

  • 52. Oxidation resistance of LDL in hypertriglyceridaemic patients treated with ciprofibrate.
    Nagyová A; Raslová K; Ginter E
    Physiol Res; 1998; 47(3):185-90. PubMed ID: 9803483
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ciprofibrate in the therapy of type II hypercholesterolemia. A double-blind trial.
    Illingworth DR; Olsen GD; Cook SF; Sexton GJ; Wendel HA; Connor WE
    Atherosclerosis; 1982 Aug; 44(2):211-21. PubMed ID: 6753860
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
    Rizos E; Bairaktari E; Ganotakis E; Tsimihodimos V; Mikhailidis DP; Elisaf M
    J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):219-26. PubMed ID: 12490967
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
    Broeders N; Knoop C; Antoine M; Tielemans C; Abramowicz D
    Nephrol Dial Transplant; 2000 Dec; 15(12):1993-9. PubMed ID: 11096145
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia.
    Wolf HR
    Drugs Exp Clin Res; 1994; 20(3):109-13. PubMed ID: 7956717
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
    Maiguma T; Fujisaki K; Itoh Y; Makino K; Teshima D; Takahashi-Yanaga F; Sasaguri T; Oishi R
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar; 367(3):289-96. PubMed ID: 12644902
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Induction of peroxisome proliferation and hepatic tumours in C57BL/6N mice by ciprofibrate, a hypolipidaemic compound.
    Rao MS; Dwivedi RS; Subbarao V; Reddy JK
    Br J Cancer; 1988 Jul; 58(1):46-51. PubMed ID: 2901849
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography.
    Masnatta LD; Cuniberti LA; Rey RH; Werba JP
    J Chromatogr B Biomed Appl; 1996 Dec; 687(2):437-42. PubMed ID: 9017468
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolism of apolipoproteins AI and AII in a patient with paradoxical reduction in high-density lipoprotein due to ciprofibrate.
    Beghin L; Capps N; Duhal N; Davies J; Staels B; Luc G
    Ann Clin Biochem; 1999 Jul; 36 ( Pt 4)():523-5. PubMed ID: 10456219
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.